Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Biogen Idec

(

BIIB

) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.0%. By the end of trading, Biogen Idec rose $10.26 (3.6%) to $295.88 on heavy volume. Throughout the day, 2,705,915 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1,114,200 shares. The stock ranged in a price between $284.51-$297.98 after having opened the day at $286.54 as compared to the previous trading day's close of $285.62. Other companies within the Drugs industry that increased today were:

Prima Biomed

(

PBMD

), up 38.9%,

Ariad Pharmaceuticals

(

ARIA

), up 35.7%,

ImmunoCellular Therapeutics

(

IMUC

), up 35.7% and

IntelliPharmaCeutics International

(

IPCI

), up 19.0%.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $59.6 billion and is part of the health care sector. The company has a P/E ratio of 35.5, above the S&P 500 P/E ratio of 17.7. Shares are up 72.5% year to date as of the close of trading on Friday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates

Biogen Idec

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front,

Mast Therapeutics

TheStreet Recommends

(

MSTX

), down 38.6%,

Bacterin International Holdings

(

BONE

), down 15.9%,

Merus Labs International

(

MSLI

), down 10.4% and

Agios Pharmaceuticals

(

AGIO

), down 10.0% , were all laggards within the drugs industry with

Bristol-Myers Squibb Company

(

BMY

) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null